Tandem CEO John Sheridan described the quarter as a "transitional time," as the company works through a limited launch of its new Mobi pump and prepares for integrations with CGMs. The company has faced increased pressure as competitor Insulet has grown quickly with its patch-pumps, and Medtronic brought a new device to the U.S. after resolving a warning letter. Tandem reported total revenues of $185.6 million, a 9% decrease year over year. Shares of the company have decreased by 17% over the past month.